JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Summers, S. A.
Right arrow Articles by Birnbaum, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Summers, S. A.
Right arrow Articles by Birnbaum, M. J.

J Biol Chem, Vol. 274, Issue 34, 23858-23867, August 20, 1999


Differentiation-dependent Suppression of Platelet-derived Growth Factor Signaling in Cultured Adipocytes*

Scott A. SummersDagger , Eileen L. WhitemanDagger §, Han Choparallel **, Lorraine Lipfert, and Morris J. BirnbaumDagger Dagger

From the Howard Hughes Medical Institute, The Cox Institute, the § Cell and Molecular Biology Graduate Group, and the parallel  Departments of Biology and Medicine, University of Pennsylvania Medical School, Philadelphia, Pennsylvania 19104

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

A critical component of vertebrate cellular differentiation is the acquisition of sensitivity to a restricted subset of peptide hormones and growth factors. This accounts for the unique capability of insulin (and possibly insulin-like growth factor-1), but not other growth factors, to stimulate glucose uptake and anabolic metabolism in heart, skeletal muscle, and adipose tissue. This selectivity is faithfully recapitulated in the cultured adipocyte line, 3T3-L1, which responds to insulin, but not platelet-derived growth factor (PDGF), with increased hexose uptake. The serine/threonine protein kinases Akt1 and Akt2, which have been implicated as mediators of insulin-stimulated glucose uptake, as well as glycogen, lipid, and protein synthesis, were shown to mirror this selectivity in this tissue culture system. This was particularly apparent in 3T3-L1 adipocytes overexpressing an epitope-tagged form of Akt2 in which insulin activated Akt2 10-fold better than PDGF. Similarly, in 3T3-L1 adipocytes, only insulin stimulated phosphorylation of Akt's endogenous substrate, GSK-3beta . Other signaling molecules, including phosphatidylinositol 3-kinase, pp70 S6-kinase, mitogen-activated protein kinase, and PHAS-1/4EBP-1, did not demonstrate this selective responsiveness to insulin but were instead activated comparably by both insulin and PDGF. Moreover, concurrent treatment with PDGF and insulin did not diminish activation of phosphatidylinositol 3-kinase, Akt, or glucose transport, indicating that PDGF did not simultaneously activate an inhibitory mechanism. Interestingly, PDGF and insulin comparably stimulated both Akt isoforms, as well as numerous other signaling molecules, in undifferentiated 3T3-L1 preadipocytes. Collectively, these data suggest that differential activation of Akt in adipocytes may contribute to insulin's exclusive mediation of the metabolic events involved in glucose metabolism. Moreover, they suggest a novel mechanism by which differentiation-dependent hormone selectivity is conferred through the suppression of specific signaling pathways operational in undifferentiated cell types.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Under the appropriate conditions, 3T3-L1 fibroblasts differentiate into cells with an adipocyte phenotype characterized by the accumulation of triglyceride and increased sensitivity to insulin. In these differentiated cells, as well as rat and human adipocytes, insulin accelerates glucose entry by effecting the translocation of glucose transporter 4 (GLUT4)1 from intracellular stores to the plasma membrane (1). Subsequently, insulin stimulates metabolic pathways to promote storage of the incoming glucose as glycogen or triglyceride. In this capacity, insulin stands apart from other growth factors, such as platelet-derived growth factor (PDGF), which activate remarkably similar signaling cascades yet are incapable of eliciting these metabolic events (2-8). A clear explanation of how these very similar signaling pathways elaborate such radically different physiological responses in this differentiated tissue has remained elusive, although compartmentalization of signaling molecules has been proposed (9).

Both insulin and PDGF activate their respective tyrosine kinase receptors to phosphorylate key residues on a "docking protein" or the receptor, respectively, which recruits multiple adaptor proteins. Recruited proteins include the GDP exchange factor Son of Sevenless, or SOS, which activates the Ras/Raf/mitogen-activated protein kinase cascade, or the p85 regulatory subunit of PI3-kinase, which stimulates signaling pathways ultimately leading to pp70 S6-kinase (10, 11), 4EBP1/PHAS-1 (12), or Akt/PKB activation (13). PI3-kinase is strongly implicated in both metabolic and mitogenic signaling (14), as is its downstream effector Akt (15-17).

This paper reports experiments aimed at understanding the mechanism by which adipocytes develop ligand selectivity such that insulin, but not PDGF, stimulates anabolic metabolism. We assessed the ability of insulin and PDGF to regulate numerous signaling molecules, particularly PI3-kinase and Akt isoforms 1 and 2, due to their relevance to anabolic metabolism (18-21). We were particularly interested in Akt2, primarily because of two recent reports suggesting a role for this particular isoform in GLUT4 translocation (22, 23). The relative effectiveness of PDGF and insulin at activating different Akt isoforms in 3T3-L1 adipocytes has been unclear. Two laboratories (24, 25) reported that insulin phosphorylates Akt on a key regulatory residue much more strongly than does PDGF, whereas a third group reported that PDGF stimulates Akt kinase activity at least 50-60% as well as insulin (26). None of these studies distinguished between the relative sensitivity of different Akt isoforms.

In the work presented below, we demonstrate that both Akt isoforms are selectively responsive to insulin, and not PDGF, in 3T3-L1 adipocytes. PDGF still activated numerous other signaling molecules, including PI3-kinase, pp70 S6-kinase, 4EBP1/PHAS-1, and mitogen-activated protein kinase, effectively in this tissue. PDGF was also a potent stimulator of both forms of Akt in the precursor 3T3-L1 fibroblasts, suggesting that 3T3-L1 differentiation specifically suppresses this signaling pathway. These experiments suggest a mechanism by which redundant signaling pathways functional in precursor cells can be altered to serve specific regulatory functions in differentiated tissues.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Antibodies and Reagents-- Polyclonal sheep anti-GLUT4 antibodies were raised against a glutathione S-transferase fusion protein encoding the last 31 amino acids of the GLUT4 carboxyl terminus (glutathione S-transferase-ISATFRRTPSLLEQEVKPSTELEYLGPDEND). Polyclonal rabbit anti-Akt antibodies were raised against the carboxyl-terminal sequences CHFPQFSYSASGTA in Akt1 and CDQTHFPQFSYSASIRE in Akt2. Polyclonal rabbit anti-phospho-S6 antibodies were raised against the major phosphorylation site in the ribosomal S6 subunit (CRRLpSpSPLRApSTSKpSEEpSQK; where pS represents phosphoserine). Anti-phospho-mitogen-activated protein kinase, phospho-Akt, and phospho-GSK antibodies were purchased from Promega (Madison, WI), New England Biolabs (Beverly, MA), and Quality Controlled Biochemicals (Hopkintown, MA), respectively. Phospho-Akt antibodies were directed against the Ser473 or Thr308 phosphorylation sites, while those against phospho-GSK recognize the Ser9 phosphorylation site. Monoclonal mouse anti-GSK-3beta antibodies were purchased from Transduction Laboratories (Lexington, KY). Agarose-bound anti-phosphotyrosine antibodies were from Upstate Biotechnology, Inc. (Lake Placid, NY). Anti-hemagglutinin antibodies were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-pp70 S6-kinase antibodies and glutathione S-transferase S6 peptide substrate were generously donated by Margaret Chou (University of Pennsylvania). Anti-PHAS-1 antibodies were kindly provided by John Lawrence (University of Virginia). Wortmannin was purchased from Sigma, and porcine insulin was a gift from Lilly. PDGF-BB was purchased from Life Technologies, Inc.

Akt Constructs, Retroviral Infection, and Cell Culture-- 3T3-L1 fibroblasts were differentiated into adipocytes 2 days postconfluence in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 1 µg/ml dexamethasone, and 112 µg/ml isobutylmethylxanthine. After 3 days, cells were maintained in DMEM supplemented with 10% fetal bovine serum. Prior to analysis, 3T3-L1 adipocytes were serum-starved as described in the figure legends. Cells were subsequently stimulated with either 100 nM insulin or 50 ng/ml PDGF.

The mouse Akt1 and human Akt2 constructs were generously provided by Phillip Tsichlis and Joseph Testa, respectively, of the Fox Chase Cancer Center (Philadelphia, PA). The HA-tagged Akt2 construct was generated by PCR using the cDNA encoding Akt2 as a template and the primers 5'-GCC ATC CGA AAG CTT GCT GCC ACC ATG TAC CCT TAT GAT GTG CCA GAT TAT GCC AAT GAG GTG TCT GTC ATC-3' (forward) to generate a hemagglutinin epitope tag at the N terminus of the protein and HindIII restriction site and 5'-ACA TAA TGC AGA TCT TCA CTC GCG GAT GCT GGC CGA GTA-3' (reverse) to create a BglII site. Akt1, Akt2, and the newly generated HA-Akt2 were then cloned into the murine retroviral vector pLNCX1, which bears a neomycin resistance gene to allow for selection of infected cells. All constructs were sequenced, and no errors were found. The constructs were packaged into replication-incompetent retrovirus following CaPO4 transfection into ecotropic Phoenix cells. Supernatants containing the retrovirus encoding HA-Akt2 were used to infect 3T3-L1 fibroblasts using the method of Hudson et al. (1992). Cells infected with the retrovirus were selected with 800 µg/ml G418 (active concentration), and colonies of G418-resistant cells were pooled.

Glucose Uptake and GLUT4 Translocation Assays-- Methods for measuring glucose uptake rates and plasma membrane GLUT4 levels (using the plasma membrane "sheet" assay) have been described (21).

Protein Immunoblotting, Immunoprecipitation, and Activity-- Western blots of total cell lysates were prepared and analyzed as described previously (27). Akt kinase assays were conducted as described previously (27) except that Akt kinase assays were conducted for only 15 min. Phospho-Akt and phospho-GSK antibodies were used at concentrations recommended by the manufacturer. Phosphotyrosine-containing proteins were immunoprecipitated by solubilizing cells as described for Akt kinase assays and incubating with 20 µl of agarose-conjugated anti-phosphotyrosine antibodies. Following a 1-3-h incubation at 4 °C, agarose was washed three times in ice-cold lysis buffer without protease inhibitors and solubilized in Laemmli sample buffer. GSK was immunoprecipitated identically with the exception that monoclonal anti-GSK antibodies were coupled to agarose-conjugated anti-mouse antibody. PI3-kinase assays were performed using methods previously described (28).

For pp70 S6-kinase assays, cells were harvested in lysis buffer (7 mM K2HPO4, 3 mM KH2PO4, 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM beta -glycerophosphate, 0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, and inhibitors 1 mM sodium orthovanadate, 1 mM dithiothreitol, 10 µg/ml leupeptin, 10 µg/ml pepstatin, pH 7.3), incubated on ice for 10 min, and centrifuged at 23,000 × g for 10 min at 4 °C. Cleared lysates (~1 mg of protein) were immunoprecipitated with anti-pp70 antibody (1.5-2 h, 4 °C) followed by the addition of activated staphylococcus (1 h, 4 °C). Immune complexes were washed once with each of the following buffers: buffer A (10 mM Tris, pH 7.2, 100 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate with inhibitors, pH 7.2), high salt buffer (10 mM Tris, 1 M NaCl, 0.1% Nonidet P-40 with inhibitors, pH 7.2), and ST buffer (100 mM Tris, 150 mM NaCl with inhibitors, pH 7.2). Kinase reactions were performed by adding 30 µl of kinase mixture to each immune complex (20 mM HEPES, pH 7.2, 10 mM MgCl2, 1 mg/ml BSA, 50 µM ATP, 0.03 µg of protein kinase inhibitor, 1-2 µg of glutathione S-transferase S6 peptide substrate, and 10 µCi of [32P-gamma ]ATP) and incubating each sample 10 min in a 30 °C water bath. Reactions were stopped by the addition of Laemmli sample buffer. Samples were analyzed by SDS-PAGE (12% gel), and 32P incorporation was quantitated by PhosphorImager analysis (Molecular Dynamics, Inc., Sunnyvale, CA).

mRNA Isolation, RT-PCR, and Restriction Analysis-- mRNA was isolated from 3T3-L1 cells before and after differentiation using the MicroPoly(A) PureTM mRNA isolation kit from Ambion. Approximately 50 ng of mRNA was reverse transcribed for 1 h at 48 °C by avian myeloblastosis virus reverse transcriptase for first strand cDNA synthesis primed by the antisense primer (5'-CTGGCTGAGTAGGAGAACTGGGG-3') after a brief denaturation of the template and primer for 2 min at 94 °C. Tfl DNA polymerase was used for second strand synthesis and PCR, primed by the antisense primer and the sense primer (5'-CCTGCCCTTCTACAACCAGGACC-3'). Amplification resulted from 40 cycles of denaturation, annealing, and extension for 30 s at 94 °C, 1 min at 60 °C, and 1 min at 68 °C, respectively. The sense primer corresponds to Akt1 nucleotides 1038-1060 or Akt2 nucleotides 1041-1063. Antisense primer corresponds to Akt1 nucleotides 1408-1430 or Akt2 nucleotides 1411-1433. RT-PCR reagents and protocols are derived from the ACCESS RT-PCR System (Promega). Other RT-PCR systems (Perkin-Elmer) produced the same results.

The RT-PCR products were purified by using the QIAquickTM PCR purification kit (QIAGEN) and digested overnight with excess units of BstEII (New England Biolabs) at 60 °C. The digested RT-PCR products were resolved by 1.4% agarose, 1× TBE gel electrophoresis and visualized by ethidium bromide staining. Control for completion of digestion was confirmed by digesting PCR product using cloned mouse Akt1 cDNA.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Several groups have found that PDGF is incapable of activating glucose uptake in 3T3-L1 adipocytes (5, 7). Nonetheless, there are two reports in which PDGF does stimulate glucose uptake in wild-type 3T3-L1 adipocytes (29) or rat adipocytes overexpressing PDGF receptors (30). To determine whether PDGF is capable of activating glucose transport and GLUT4 translocation in the 3T3-L1 adipocytes used in our laboratory, we assayed these events after a 10-min treatment with either insulin (100 nM) or PDGF (50 ng/ml). Insulin, but not PDGF, stimulated both the uptake of 2-[3H]deoxyglucose (Fig. 1A) and the appearance of cell surface GLUT4 (Fig. 1B). In light of the similarities among the known signaling mechanisms for either agonist, one explanation for this difference was that PDGF additionally activated "inhibitory mechanisms" that prevented its enhancement of certain metabolic events. While previous studies have demonstrated the existence of inhibitory "cross-talk" between insulin and PDGF pathways when PDGF is added prior to insulin (24, 31), simultaneous addition of the peptides had not been investigated in detail. As shown in Fig. 1, A and B, concomitant addition of insulin and PDGF resulted in stimulation of glucose uptake and GLUT4 translocation equivalent to insulin alone.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of PDGF and/or insulin on metabolic signaling in differentiated 3T3-L1 adipocytes. A, the uptake of 2-[3H]deoxyglucose was measured following a 10-min stimulation with PDGF (50 ng/ml) and/or insulin (100 nM) of differentiated 3T3-L1 adipocytes grown in 12-well dishes. The nonspecific background measured in cells exposed to cytochalasin B in the absence of insulin was subtracted from all values. The results shown are means ± S.E. of three independent experiments performed in triplicate. B, adipocytes grown on coverslips were treated as above before preparation of plasma membrane sheets. The plasma membrane sheets were subjected to immunofluorescence microscopy using polyclonal sheep anti-GLUT4 antibodies and rhodamine-conjugated anti-sheep secondary antibodies. Images were captured using a digital camera. Data are representative of four independent experiments. C, 3T3-L1 fibroblasts or adipocytes were serum-starved 20-24 h in DMEM containing 10 mM HEPES and 0.5% BSA before stimulation with either 50 ng/ml PDGF or 1 µM insulin for 10 min. Total cell lysates (40 µg of protein) were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with either anti-phosphotyrosine or anti-phospho-mitogen-activated protein kinase antibodies. Data are representative of two independent experiments. D, 3T3-L1 adipocytes were serum-starved for 2 h in Leibovitz's L-15 medium containing 0.2% BSA and then stimulated with PDGF (50 ng/ml) and/or insulin (100 nM) for 10 min. PI3-kinase was immunoprecipitated using anti-phosphotyrosine antibody, and kinase activity was assayed using phosphatidylinositol as substrate. Kinase reactions were spotted onto thin layer chromatography plates and visualized by autoradiography. Data are representative of two independent experiments.

Despite PDGF's inability to activate these metabolic responses, PDGF does signal other events as effectively as insulin in this cell type. In both 3T3-L1 fibroblasts and adipocytes, insulin stimulated the tyrosine phosphorylation of insulin and/or IGF-1 receptors, while PDGF induced tyrosine phosphorylation of the PDGF receptor (Fig. 1C, upper panel). Moreover, in both cell types, insulin and PDGF stimulated phosphorylation of mitogen-activated protein kinase (Fig. 1C, lower panel). Since PI3-kinase is critical for activation of anabolic metabolism, as well as signaling molecules such as Akt and pp70 S6-kinase (10, 13, 18, 32), its activity in anti-phosphotyrosine immunoprecipitates was measured. Insulin and PDGF treatment, respectively, stimulated PI3-kinase 100-fold over basal level, and the precipitated activity roughly doubled when both agonists were added simultaneously (Fig. 1D). These results are consistent with prior reports that PDGF receptors mediate activation of PI3-kinase in 3T3-L1 adipocytes, but this is not sufficient for activation of glucose transport (7).

As described above, prior studies have been contradictory regarding whether Akt is activated by PDGF in 3T3-L1 adipocytes. Two reports have shown that insulin is significantly more potent than PDGF in increasing Akt phosphorylation by using phosphospecific antisera directed against the regulatory Ser473 site on Akt1. In contrast, Tanti et al. (26) found that PDGF is quite effective at stimulating Akt activity as measured in the immune complex, achieving a level of activation that is at least 50% that induced by insulin. In addition to being contradictory, these prior studies have not distinguished between activation of each isoform. To resolve these apparent discrepancies, we used four different approaches to evaluate the regulation of Akt isoforms 1 and 2 by insulin and PDGF in 3T3-L1 fibroblasts and adipocytes. First, we used anti-phospho-Ser473 antisera, which, as shown below, specifically recognizes phosphorylated Akt1, but not Akt2, and anti-phospho-Thr308 antisera, which recognizes both Akt1 and Akt2 isoforms. Second, we produced an antibody specific for Akt2 that could detect both an agonist-induced mobility shift when the proteins were separated on SDS-polyacrylamide gels and could immunoprecipitate endogenous Akt2 kinase activity from intact cells. Third, we expressed an epitope-tagged form of Akt2 in 3T3-L1 cells and then measured the shift and kinase activity of this construct using antibodies against the HA epitope. And fourth, we measured the degree of phosphorylation of the Akt substrate GSK-3beta in vivo, which serves as a marker of endogenous Akt kinase activity in the intact cell.

To characterize the isoform preference for the phosphospecific antibody directed against the regulatory Ser473 phosphorylation site, Akt1 and Akt2 isoforms were expressed in 3T3-L1 cells. Using an antibody raised against the carboxyl terminus of Akt1 but that actually recognizes both isoforms, we demonstrated that these proteins were overexpressed severalfold and that Akt2 migrated slightly faster than Akt1 when resolved on SDS-polyacrylamide gels (Fig. 2A). Electrophoresis conditions were not optimized in this experiment to detect an agonist-induced mobility shift, which is generally less pronounced using this antibody as compared with the Akt2-specific antibody described below. When the phospho-Ser473 antibody was used to investigate Akt phosphorylation in these lysates, it detected phosphorylated Akt in Akt1-expressing 3T3-L1 adipocytes that were stimulated by insulin but not PDGF (Fig. 2B, upper panel). However, as seen in longer exposures (Fig. 2B, lower panel), the antibody only detected endogenous Akt and not the overexpressed construct in cells stably expressing Akt2. Prolonged exposure of the blots also indicated that overexpressed Akt1 was recognized by the anti-phospho-Ser473 antibody to some degree under basal conditions, but this was augmented only by insulin and not PDGF. Faint reactivity with the phosphospecific Akt antibody was sometimes observed in the PDGF-stimulated adipocyte lysates, but it was always markedly less than that seen in response to insulin. Collectively, these results indicate that the anti-phospho-Ser473 antibody is specific for the Akt1 isoform and that insulin stimulates Akt1 phosphorylation much more potently than does PDGF in 3T3-L1 adipocytes.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Insulin-specific Ser473 phosphorylation of Akt1 in 3T3-L1 adipocytes. A (upper panel), 3T3-L1 adipocytes stably expressing an empty vector, Akt1, or Akt2 were serum-starved for 20-24 h in DMEM containing 10 mM HEPES and 0.5% BSA before treatment without (-) or with insulin (I, 1 µM) for 10 min. Total cell lysates were resolved by SDS-PAGE, transferred to nitrocellulose, and detected with antibodies directed against the carboxyl terminus of Akt1 (anti-Akt). In these experiments, electrophoresis conditions were not optimized to resolve insulin-stimulated mobility shifts, which are evident in later figures. B, these same cell lines were treated as above, except some cells received PDGF (P, 50 ng/ml). Total cell extracts were again resolved by SDS-PAGE, transferred to nitrocellulose, and probed with anti-phospho-Akt antibodies directed against the Ser473 phosphorylation site (anti-PAkt (S473)). Detection in all cases was by enhanced chemiluminescence, and representative blots are shown following a short (30-s) or long (4-min) exposure.

To investigate whether PDGF affected Akt1 in the adipocyte precursor cells, 3T3-L1 fibroblasts, we again investigated PDGF's ability to increase phosphorylation of Akt1 using the phospho-Ser473-specific antibody. As demonstrated in Fig. 3, PDGF stimulated Ser473 phosphorylation comparably with insulin in 3T3-L1 fibroblasts. Insulin was used at a concentration of 1 µM, and under these conditions it is likely to be binding to IGF-1 receptors. Akt1 is also phosphorylated on a second regulatory site, Thr308. Using a phosphospecific antibody that recognizes this second regulatory site (as well as the analogous Thr309 site in Akt2), we found that this residue was phosphorylated in response to both insulin and PDGF in 3T3-L1 fibroblasts but was selectively responsive to insulin in differentiated 3T3-L1 adipocytes (Fig. 3). Phosphorylation of either site was blocked by pretreatment with wortmannin, confirming their PI3-kinase dependence in adipocytes. These studies suggest that differentiation actually suppresses signaling events "downstream" of PI3-kinase, and suggests a more complicated pattern of regulation of Akt1.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of differentiation on Akt1 phosphorylation. 3T3-L1 fibroblasts (left panels) and adipocytes (right panels) were serum-starved for 2 h in Leibovitz-15 medium containing 0.2% BSA before treatment with PDGF (50 ng/ml; PDGF) or insulin (1 µM for fibroblasts, 100 nM for adipocytes; Insulin) for 10 min. Adipocytes were pretreated with (+) or without (-) 100 nM wortmannin for 30 min prior to the addition of insulin. Total cell extracts were prepared, resolved by SDS-PAGE, transferred to nitrocellulose, and probed with anti-phospho-Ser473 or anti-phospho-Thr308 antibodies.

Because of the isoform specificity of the phospho-Akt antibody, the previously published studies could not address whether the more relevant Akt2 isoform was differentially phosphorylated in 3T3-L1 adipocytes. An indication of the importance of investigating Akt2 is its altered expression during the course of 3T3-L1 differentiation. This was demonstrated using a quantitative reverse transcription PCR assay. An oligonucleotide primer pair identical in both isoforms was used for RT-PCR amplification. The regions amplified between the two primers in Akt1 and Akt2 were identical in size and highly similar in sequence; thus, the PCR amplification of both isoforms should occur with virtually the same efficiency in a single reaction mixture. After the RT-PCR, the product was subjected to a restriction digest at a site present in Akt1, but not Akt2, and the products were resolved by gel electrophoresis to determine which isoform amplification was greater relative to the other. Comparison between 3T3-L1 fibroblasts and 3T3-L1 adipocytes showed a marked increase in the level of the undigested versus digested fragment of the PCR product, indicating an increase in the ratio of Akt2 mRNA relative to Akt1 mRNA upon differentiation (Fig. 4). Altomare et al. (33) report a similar relationship between Akt1 or Akt2 mRNA levels during the course of 3T3-L1 differentiation using Northern analysis.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 4.   Akt2 is up-regulated upon adipogenesis relative to Akt1 as determined by quantitative RT-PCR. A, schematic representation of the RT-PCR strategy. The primers depicted correspond to sequences that are identical between Akt1 and Akt2 and amplify a 392-bp region. Reverse transcription of isolated mRNA with the antisense primer and subsequent PCR with sense and antisense primers results in amplification of both Akt1 and Akt2 in the same reaction. However, the amplified 392-bp region of Akt1 has a BstEII site unique to it and absent in the corresponding region of Akt2. BstEII digestion of the Akt1 fragment produces two fragments (243 and 149 bp), while Akt2 is resistant to BstEII digestion. The intensity of the 392-bp fragment reflects the amount of Akt2, and while the intensity of the 243- and 149-bp fragment reflects the amount of Akt1. B, ethidium bromide-stained agarose gel eletrophoresis showing that Akt2 relative to Akt1 is up-regulated in 3T3-L1 cells after differentiation into adipocytes; 3T3-L1 fibroblasts were differentiated into adipocytes in culture. mRNA was isolated before and after differentiation and used for the RT-PCR/restriction digest assay described in A. Upon differentiation, the intensity of the 392-bp band (Akt2) increases relative to the 243- and 149-bp bands (Akt1). The white asterisks highlight the 500-bp band of a 100-bp ladder (New England Biolabs).

Due to the likely relevance of Akt2 to metabolic signaling, we conducted an exhaustive series of experiments to detect whether Akt2 was also differentially stimulated by insulin, and not PDGF, in 3T3-L1 adipocytes. An Akt2-specific antibody raised against a carboxyl-terminal regulatory domain was produced. This antibody preferentially recognized the overexpressed Akt2, but not Akt1 (Fig. 5A). The Akt2-specific antibody also detected a dramatic electrophoretic mobility shift in parental 3T3-L1 cells in response to stimulation and detected increased Akt2 expression during the course of differentiation (Fig. 5B). Insulin, but not PDGF, elicited this mobility shift in 3T3-L1 adipocytes (Fig. 5C). The PI3-kinase inhibitor wortmannin completely inhibited the mobility shift in adipocytes (Fig. 5C), confirming that insulin promoted phosphorylation of Akt2 through a PI3-kinase-dependent mechanism in this cell type. PDGF was capable of eliciting this mobility shift in 3T3-L1 fibroblasts (Fig. 5C).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Insulin-specific stimulation of an Akt2 electrophoretic mobility shift. A, the lysates used in Fig. 2A were resolved by SDS-PAGE, transferred to nitrocellulose, and incubated with antibodies directed against the carboxyl terminus of Akt2. B, the effect of adipocyte differentiation on Akt2 expression was evaluated. 3T3-L1 fibroblasts underwent the differentiation protocol described, and lysates were prepared starting at day 0 (just before the addition of differentiation medium) and ending on day 9. Prior to lysis, cells were serum-starved as described in Fig. 1 and then stimulated without (-) or with 1 µM insulin (I) for 10 min. Following resolution on SDS-PAGE and transfer to nitrocellulose, proteins were detected with anti-Akt2 antibodies and enhanced chemiluminescence. C, 3T3-L1 fibroblasts (left panel) and adipocytes (right panel) were treated without or with (+W) wortmannin (250 nM) 30 min prior to stimulation with PDGF (PDGF, 50 ng/ml) or insulin (Ins, 1 µM for fibroblasts, 100 nM for adipocytes) for 10 min.

As described above, a prior study reported that PDGF significantly stimulated endogenous Akt kinase activity when measured in an immune complex assay (26). Using the isoform-specific Akt2 antibodies, we similarly observed a significant PDGF stimulation of Akt2 kinase activity in immune complex assays (Fig. 6). Because activation of Akt kinase did not correlate with phosphorylation on the major regulatory sites, Ser473 and Thr308, there was concern that some of the activity measured in the immune complex might be due to another hormone-sensitive kinase contaminating the immune complex assay. To evaluate this, HA-tagged Akt2 was expressed in 3T3-L1 adipocytes at levels 2-5 times higher than endogenous Akt2. If Akt2 were associating with a limiting kinase also activated by insulin, overexpression should allow a more definitive assay. Moreover, use of the anti-HA antibody also excludes potential cross-reactivity of the Akt2 antibody with another protein kinase. Western blot analysis of the electrophoretic mobility shift of the overexpressed HA-Akt2 construct revealed that both insulin and PDGF retarded its electrophoretic mobility in fibroblasts (Fig. 7A), but only insulin elicited the shift in adipocytes (Fig. 7C). This change in mobility could be detected with both anti-HA and anti-Akt2 antibodies. Kinase activity of the overexpressed Akt2 was ascertained in immunoprecipitates using anti-HA antisera. In fibroblasts, PDGF was significantly more effective than insulin at stimulating HA-Akt2 kinase activity (Fig. 7B). Following differentiation, however, insulin's stimulation of HA-Akt2 was roughly 10-fold greater than that of PDGF (Fig. 7D). Similar results were obtained using the anti-Akt2 antibodies in the overexpressing cell lines, although the antibody precipitated less total activity (data not shown).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of differentiation on Akt2 kinase activity. 3T3-L1 fibroblasts (left panels) and adipocytes (right panels) were serum-starved for 20-24 h in DMEM containing 10 mM HEPES and 0.5% BSA before treatment with PDGF (50 ng/ml; PDGF) or insulin (1 µM, Ins) for 10 min. Akt2 in vitro immune complex kinase reactions were performed as described, and 32P-incorporation into histone 2B was visualized by autoradiography or quantitated by PhosphorImager analysis (Molecular Dynamics). Results shown are the means ± S.E. of three independent experiments.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 7.   Electrophoretic mobility and kinase activity of HA-Akt2 in 3T3-L1 fibroblasts and adipocytes. 3T3-L1 fibroblasts (A and B) or adipocytes (C and D) overexpressing HA-Akt2 were serum-starved for 2 h in Leibovitz's L-15 medium containing 0.2% BSA before treatment with PDGF (50 ng/ml; P) or insulin (1 µM for fibroblasts, 100 µM for adipocytes; I) for 10 min. A and C, total cell extracts were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with anti-HA or anti-Akt2 antibodies. B and D, Akt in vitro immune complex kinase reactions were performed as described using anti-HA antibodies for immunoprecipitation. 32P incorporation into histone 2B was visualized by autoradiography and quantitated by PhosphorImager analysis (Molecular Dynamics). Results shown are the means ± S.E. of three independent experiments.

As a final means for ascertaining Akt kinase activity, we evaluated the degree of phosphorylation of an endogenous substrate for Akt, GSK-3beta . A prior study (25) measured the effects of insulin and PDGF on GSK-3beta kinase activity and found that PDGF inhibited GSK-3beta kinase activity about half as well as insulin. However, several molecules have been reported to affect GSK-3beta kinase activity (34), while only Akt is known to phosphorylate GSK-3beta on the regulatory serine 9 residue. Moreover, GSK-3beta kinase activity is inhibited only ~50% in response to insulin or other agonists (25, 35), while changes in GSK-3beta phosphorylation are much easier to detect. Thus, we chose to measure GSK-3beta phosphorylation on the Akt target residue, serine 9, as an indication of endogenous Akt kinase activity. GSK-3beta was immunoprecipitated from insulin- and PDGF-stimulated cells using monoclonal anti-GSK-3beta antibodies and subjected to Western blotting with an antibody directed against the phosphorylated serine 9 site of GSK3beta . In fibroblasts, both insulin and PDGF stimulated GSK-3beta phosphorylation; in adipocytes, however, PDGF-induced GSK-3beta phosphorylation was much less pronounced (Fig. 8). Thus, in vivo phosphorylation of an endogenous substrate of Akt precisely reflects the insulin/PDGF specificity suggested by phosphorylation of Akt or the in vitro activity of overexpressed Akt. This is perhaps the best measure of Akt kinase activity, since this is not subject to potential artifacts associated with measuring immunoprecipitated kinase activity but rather is likely to reflect the total amount of Akt kinase activity present in the intact cell.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 8.   Akt kinase activity in 3T3-L1 fibroblasts and adipocytes measured by phosphorylation of GSK-3beta , an in vivo substrate. 3T3-L1 fibroblasts (left) and adipocytes (right) were serum-starved for 2 h in Leibovitz's L-15 media containing 0.2% BSA before treatment with PDGF (50 ng/ml; P), insulin (1 µM; I), or no stimulation (-). GSK-3 was immunoprecipitated using anti-GSK-3beta antibodies and resolved by SDS-PAGE. GSK-3 phosphorylation was detected by probing Western blots with anti-phospho-GSK-3 antibodies. Data are representative of two independent experiments.

The ability of PDGF to activate PI3-kinase as measured in the immune complex, but not stimulate Akt, raised the question of whether signaling-competent 3'-phosphoinositides were being generated in response to PDGF in the intact cell. Thus, we chose to look at two downstream targets that require polyphosphoinositide production for activation. PDGF reportedly stimulates pp70 S6-kinase activity, and a mobility shift in 3T3-L1 adipocytes (24) and, in other cell types, PI3-kinase is required for pp70 S6-kinase activation (11). In both the 3T3-L1 fibroblasts and adipocytes used in this study, both PDGF and insulin stimulated phosphorylation of pp70 S6-kinase as demonstrated by an upward electrophoretic mobility shift on Western blots (Fig. 9A). Two other assays revealed that adipocyte pp70 S6-kinase was activated comparably by both insulin and PDGF in 3T3-L1 adipocytes: 1) both insulin and PDGF activated pp70 S6-kinase roughly 3-4-fold as measured by immune complex kinase assays using ribosomal S6 peptide as substrate (Fig. 9B); and 2) PDGF and insulin both induced the phosphorylation in vivo of pp70 S6-kinase's endogenous substrate, ribosomal protein S6 (Fig. 9B). Phosphorylation of S6 was detected by probing total cell lysates with anti-phospho-S6 antibodies following stimulation of adipocytes with either PDGF or insulin. Submaximal insulin doses had similar effects on the insulin-stimulated shift of both Akt and pp70 S6-kinase, further suggesting that the two enzymes respond similarly to insulin stimulation (Fig. 9C). Finally, stimulation of pp70 S6-kinase by either insulin or PDGF was blocked by pretreatment with the PI3-kinase inhibitor wortmannin (Fig. 9D) or LY294002 (Fig. 9E), confirming PI3-kinase dependence for pp70 S6-kinase activation. These data provide confirmation that functional 3'-phosphoinositides are generated in response to PDGF, since their production is required for stimulation of pp70 S6-kinase.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 9.   Activity of pp70 S6 kinase following stimulation of 3T3-L1 adipocytes with PDGF or insulin. In A-C, 3T3-L1 fibroblasts or adipocytes were serum-starved for 2 h in KRP buffer containing 0.2% BSA. In D and E, cells were additionally stepped down in DMEM containing 10 mM HEPES and 0.5% BSA prior to the incubation in KRP. In A-E, cells were stimulated with either PDGF (50 ng/ml; P), insulin (100 nM; I), or no stimulation (-), while in C cells were stimulated with the indicated concentration of insulin, for 10 min prior to lysis. A, following stimulation, total cell lysates (50 µg of protein) from 3T3-L1 fibroblasts or adipocytes were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with anti-pp70 S6 kinase antibodies to detect an agonist-induced mobility shift. B, upper panel, following stimulation, pp70 S6-kinase was immunoprecipitated from 3T3-L1 adipocytes using polyclonal anti-pp70 antibodies, and in vitro kinase reactions were performed on the immune complexes. Reactions proceeded for 10 min at 30 °C and were resolved by SDS-PAGE. 32P incorporation into glutathione S-transferase S6 peptide was visualized by autoradiography and quantitated by PhosphorImager analysis (Molecular Dynamics). B, lower panel, total cell lysates (50 µg of protein) from stimulated 3T3-L1 adipocytes were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with anti-phospho-S6 antibodies. C, total cell lysates from 3T3-L1 adipocytes (50 µg of protein) treated with the indicated concentrations of insulin were resolved by SDS-PAGE, transferred to nitrocellulose, and probed with anti-pp70 S6 kinase or anti-Akt2 antibodies. D, the PI3-kinase inhibitor LY294002 (100 µM) was added to 3T3-L1 adipocytes 30 min prior to stimulation with insulin or PDGF. Total cell lysates were resolved by electrophoresis and detected with antibodies against pp70 S6 kinase or the phosphorylated species of ribosomal S6 protein as described above. E, the PI3-kinase inhibitor wortmannin (250 nM) was added to 3T3-L1 adipocytes for the last 30 min prior to stimulation with insulin or PDGF. Total cell lysates were resolved by electrophoresis and detected with antibodies against pp70 S6 kinase or the phosphorylated species of ribosomal protein S6. Identical results were obtained using 100 nM wortmannin.

A second signaling molecule downstream of PI3-kinase is the translational repressor PHAS-1 (also called 4EBP1). PHAS-1 is phosphorylated on multiple different sites by the protein mTOR (mammalian target of rapamycin), but the molecular events activating mTOR are a subject of debate. We evaluated the relative actions of insulin and PDGF on PHAS-1 phosphorylation, which can be detected by a reduction in electrophoretic mobility when the protein is resolved on SDS-PAGE gels (36). Like pp70 S6-kinase, PHAS-1 was phosphorylated in response to both insulin and PDGF (Fig. 10), although the former was more effective. The shift in mobility could be inhibited by wortmannin (Fig. 10) or LY294002 (data not shown). These data indicate that PDGF is capable of generating PI3-kinase-dependent signals leading to phosphorylation of pp70 S6-kinase and PHAS-1 in 3T3-L1 adipocytes.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 10.   Phosphorylation of PHAS-1 response to insulin and PDGF in 3T3-L1 adipocytes. 3T3-L1 adipocytes were serum-starved 18-24 h in DMEM with 0.5% BSA and 10 mM Hepes and then starved for an additional 2 h in KRP containing 0.2% BSA before treatment with nothing (B), PDGF (50 ng/ml; P), or insulin (100 nM; I) for 10 min. Certain samples were pretreated with 250 nM wortmannin 30 min prior to insulin. Total protein (40 µg) was resolved by SDS-PAGE, transferred to nitrocellulose, and probed with anti-PHAS-1 antibody. Identical results were obtained using 100 nM wortmannin.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The data presented in this report demonstrate that Akt isoforms 1 and 2 are activated significantly by insulin, but not PDGF, in differentiated 3T3-L1 adipocytes. Evidence supporting this conclusion includes the following: 1) insulin, but not PDGF, stimulated Akt1 phosphorylation in 3T3-L1 adipocytes, as detected using phosphospecific antibodies recognizing a regulatory Ser473 site on Akt1; 2) insulin, but not PDGF, decreased the electrophoretic mobility of Akt2 separated on polyacrylamide gels; 3) insulin, but not PDGF, stimulated phosphorylation of Akt1 and/or Akt2 on the regulatory Thr308 or Thr309 site, respectively; 4) insulin was a much more potent activator of HA-Akt2 kinase than PDGF as measured in the immune complex; and 5) insulin, but not PDGF, stimulated phosphorylation of the endogenous Akt substrate GSK-3beta . This last assay is most convincing, since it demonstrates insulin selectivity of Akt activation in the intact cell. Other signaling molecules are activated comparably in this differentiated tissue, including the upstream lipid kinase PI3-kinase and its downstream targets pp70 S6-kinase and PHAS-1. Insulin's ability to activate Akt is adipocyte-specific, since PDGF was a potent stimulator of Akt phosphorylation, electrophoretic mobility retardation, and kinase activity, as well as GSK-3beta phosphorylation, in preadipocyte 3T3-L1 fibroblasts.

The first experiments describing hormonal activation of Akt involved expressed mutant PDGF receptors (13), and in these initial studies it was determined that PI3-kinase is critical for PDGF-triggered Akt activation. Subsequent studies indicated that expression of constitutively active forms of PI3-kinase is sufficient to activate endogenous Akt (37). Several different Akt isoforms have now been identified (38, 39), all sharing a great deal of homology. These isoforms are expressed fairly ubiquitously, and they have been implicated in numerous cellular processes. Myriad studies have implicated Akt in metabolic responses to insulin. Overexpression of constitutively active forms of Akt stimulates glucose uptake and GLUT4 translocation (21, 26), as well as protein and lipid synthesis (21). Expression of dominant-negative forms of Akt confirms a role for the enzyme in insulin-stimulated glycogen (40) and protein (41) synthesis. In other tissues Akt apparently participates more generally in anti-apoptosis (42) and regulation of cell cycle (43).

The hypothesis that Akt plays a pivotal role in GLUT4 translocation has been recently challenged (41), but this topic remains controversial (44). Recently, the Akt2 isoform was found to specifically associate with GLUT4-containing vesicles and to phosphorylate GLUT4 vesicle resident proteins (22, 23). Furthermore, the sphingomyelin derivative ceramide inhibits glucose uptake and GLUT4 translocation, and this correlates with its ability to inhibit Akt phosphorylation and activation (45). Thus, although the evidence that Akt is involved in glucose uptake or GLUT4 translocation is controversial, this issue has not been resolved. Regardless, Akt's contribution to insulin-stimulated protein synthesis (41) and glycogen synthesis (40) are strongly supported by the literature, confirming at least some role for the enzyme in glucose metabolism. The data presented above indicate that Akt2 expression increases markedly during the course of 3T3-L1 differentiation (Figs. 4 and 5), further implicating a role for this isoform in insulin-stimulated metabolism.

Akt is also implicated in activation of two other signaling molecules, pp70 S6-kinase and PHAS-1/4EBP1. Overexpression of constitutively active forms of Akt stimulates phosphorylation of both molecules (13, 20), while expression of a dominant negative form blocks insulin's stimulation of pp70 S6-kinase (41). Despite these studies, a mechanism has been proposed whereby pp70 S6-kinase can be stimulated directly by the upstream kinase PDK1 and thus not require Akt for activation (46). In this paper, we present conditions where there is a lack of correlation between the activation of pp70 S6-kinase, PHAS-1/4EBP1, and Akt. Specifically, PDGF stimulates pp70 S6-kinase and PHAS-1 without significantly affecting Akt, suggesting that Akt is dispensable for pp70 S6-kinase or PHAS-1 activation under these conditions.

One hypothesis previously offered to explain PDGF's disproportionate effects on activation of glucose uptake and PI3-kinase is that PDGF does not target PI3-kinase to the appropriate subcellular compartment. Several laboratories report that PDGF-stimulated PI3-kinase is located primarily at the plasma membrane, while insulin-stimulated PI3-kinase is predominantly microsomal (2, 3). Targeting sequences found in the cytosolic IRS-1, but not the membrane-bound PDGF receptor, could account for differences in localization. Moreover, some reports indicate that insulin, but not PDGF, specifically targets PI3-kinase to GLUT4 vesicles (9). This has been recently challenged, however, since PI3-kinase was instead reported to associate with the cytoskeleton and not the GLUT4 vesicle itself (47). While this model appears attractive with regard to GLUT4 vesicles, it is inherently more difficult to explain how PDGF is capable of activating some cytosolic enzymes, such as pp70 S6-kinase, but not others, such as Akt, using such a compartmentalization model. Nonetheless, it remains a formal possiblity that PDGF receptors and PI3-kinase could specifically be sequestered from Akt in 3T3-L1 adipocytes. Overexpression of PDGF receptors reportedly stimulates glucose uptake (30), perhaps because the elevated expression of receptors saturates such sequestration events. Intriguingly, expression of PDGF receptors incapable of activating PI3-kinase still stimulates wortmannin-sensitive glucose transport (30). These mutant receptors might be liberating endogenous PDGF receptors from such sequestration mechanisms. We are currently investigating whether PDGF receptor overexpression releases the suppression of PDGF's activation of Akt.

An alternative possibility is that the activity of PI3-kinase as measured in the immune complex assay may not reflect the levels of phosphoinositides accumulated in vivo, possibly due to differences in accessibility to substrate. A prior study reports that although insulin and PDGF activate mitogen-activated protein kinase comparably, only insulin stimulates the intracellular production of the lipid product PIP3 (4). PIP3 could be critical for activation of Akt, but not pp70. An alternative mechanism for differential production of PIP3 is that PDGF, but not insulin, stimulates a localized PIP3 phosphatase.

A third possibility is that insulin stimulates other signaling event pathways in addition to those previously described that are required for complete activation of Akt. If this is the case, such mechanisms must themselves be specifically uncoupled from PDGF receptors during the course of differentiation. In another recent report (48), membrane-permeable analogs of PIP3 were found to be incapable of stimulating glucose transport. However, when these PIP3 analogs were added to wortmannin-treated cells stimulated with insulin, they were capable of stimulating transport. This experiment suggests that additional pathways are required for activation of glucose transport, and future experiments will investigate whether this is also the case for Akt.

In addition to suggesting a role for Akt in insulin-stimulated glucose metabolism, the data presented herein can be elaborated into a broader hypothesis regarding the generation of a differentiated phenotype. The development of specialized cells is accompanied by the acquisition of novel morphological and biochemical characteristics. In white adipose tissue, for example, features conferred by differentiation include a reduced central cytoskeleton, the accumulation of a large and metabolically active triglyceride droplet, and marked insulin-stimulatable glucose transport. The latter apparently depends on the induction of the GLUT4 glucose transporter, although its expression is clearly not sufficient (49). In complex, multisystem organisms, highly specialized functions are characterized by exquisitely controlled regulation, often by extracellular ligands in the form of hormones and growth factors. Thus, the mature cell must not only possess unique terminal outputs but must also display distinctive selectivity to unique arrays of extracellular signals. Based on the current data, we propose that some cells confer this specificity via selective suppression of signaling pathways present in a multipotent immature precursor cell (Fig. 11). This process stands in contrast to the development of a new response, for example the induction of a novel transporter isoform. However, the elimination of an unwanted pathway appears a parsimonious strategy for such a process as signal transduction, in which differentiated cells utilize a common set of biochemical devices assembled into distinct schemes. Nonetheless, at this point the establishment of such a strategy as broadly utilized requires further experimentation.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 11.   Model for differentiation of 3T3-L1 adipocytes. In fibroblasts, both insulin/IGF-1 and PDGF receptors couple to a diverse array of signaling pathways. Thus, either growth factor effectively activates Akt, as well as pp70 S6 kinase and mitogen-activated protein kinase. However, the fibroblast is incapable of generating an authentic metabolic response, e.g. a marked increase in glucose transport. Conversion to adipocytes is accompanied by the acquisition of metabolic outputs, conferred by the induction of GLUT4 as well as other proteins required both for augmentation of hexose flux as well as other metabolic responses. In addition, the mature adipocyte acquires specificity in terms of ligand responsiveness by selectively suppressing the ability of non-insulin growth factors, e.g. PDGF, to stimulate phosphorylation of Akt. Thus, the mature phenotype well recognized in skeletal muscle and adipose tissue displays not only a unique responsiveness in terms of the magnitude of stimulation of glucose transport by insulin, but exquisite selectivity in regard to the hormone or growth factor that elicits such a response.


    ACKNOWLEDGEMENTS

We are grateful to several individuals and organizations for contributions to this work. Margaret Chou (University of Pennsylvania) kindly donated anti-pp70 antibodies and provided invaluable technical assistance with pp70 S6-kinase assays. John Lawrence (University of Virginia) graciously donated anti-PHAS-1 antibodies. Joseph Testa (Fox Chase Cancer Center) generously provided human Akt (beta -isoform) cDNA. Cass Lutz (University of Pennsylvania) provided assistance in the typing and editing of this manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK39615 (to M. J. B.) and DK09375 (to S. A. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger These authors contributed equally to this work.

Supported by a Howard Hughes Pre-Doctoral Fellowship for the Biological Sciences.

** Supported by National Research Service Award for Training in Cell and Molecular Biology GM07229.

Dagger Dagger To whom correspondence should be addressed: Howard Hughes Medical Institute, University of Pennsylvania Medical School, 415 Curie Blvd., Philadelphia, PA 19104. Tel.: 215-898-5001; Fax: 215-573-9138; E-mail: birnbaum@hhmi.upenn.edu.

    ABBREVIATIONS

The abbreviations used are: GLUT, glucose transporter; GSK, glycogen synthase kinase; PI3-kinase, phosphatidylinositol 3-kinase; BSA, bovine serum albumin; HA, hemagglutinin; PDGF, platelet-derived growth factor; DMEM, Dulbecco's modified Eagle's medium; PCR, polymerase chain reaction; RT-PCR, reverse transcription-PCR; PAGE, polyacrylamide gel electrophoresis; bp, base pair(s).

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Birnbaum, M. J. (1992) Int. Rev. Cytol. 137A, 239-297[Medline] [Order article via Infotrieve]
2. Ricort, J. M., Tanti, J. F., Van Obberghen, E., and Le Marchand-Brustel, Y. (1996) Eur. J. Biochem. 239, 17-22[Medline] [Order article via Infotrieve]
3. Nave, B. T., Haigh, R. J., Hayward, A. C., Siddle, K., and Shepherd, P. R. (1996) Biochem. J. 318, 55-60
4. Conricode, K. M. (1995) Biochem. Mol. Biol. Int. 36, 835-843[Medline] [Order article via Infotrieve]
5. Huppertz, C., Schwartz, C., Becker, W., Horn, F., Heinrich, P. C., and Joost, H.-G. (1996) Diabetologia 39, 1432-1439[CrossRef][Medline] [Order article via Infotrieve]
6. Isakoff, S. J., Taha, C., Rose, E., Marcusohn, J., Klip, A., and Skolnik, E. Y. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10247-10251[Abstract/Free Full Text]
7. Wiese, R. J., Mastick, C. C., Lazar, D. F., and Saltiel, A. R. (1995) J. Biol. Chem. 270, 3442-3446[Abstract/Free Full Text]
8. Gould, G. S., Merrall, N. W., Martin, S., Jess, T. J., Campbell, I. W., Calderhead, D. M., Gibbs, E. M., Holman, G. D., and Plevin, R. J. (1994) Cell. Signalling 6, 313-320[CrossRef][Medline] [Order article via Infotrieve]
9. Heller-Harrison, R. A., Morin, M., Guilherme, A., and Czech, M. P. (1996) J. Biol. Chem. 271, 10200-10204[Abstract/Free Full Text]
10. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911[Abstract/Free Full Text]
11. Chung, J., Grammer, T. C., Lemon, K. P., Kazlauskas, A., and Blenis, J. (1994) Nature 370, 71-75[CrossRef][Medline] [Order article via Infotrieve]
12. Scott, P. H., Brunn, G. J., Kohn, A. D., Roth, R. A., and Lawrence, J. C. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7772-7777[Abstract/Free Full Text]
13. Burgering, M., and Coffer, P. (1995) Nature 376, 599-602[CrossRef][Medline] [Order article via Infotrieve]
14. Kapeller, R., and Cantley, L. (1994) BioEssays 16, 565-576[CrossRef][Medline] [Order article via Infotrieve]
15. Marte, B. M., and Downward, J. (1997) Trends Biochem. Sci. 22, 355-358[CrossRef][Medline] [Order article via Infotrieve]
16. Franke, T. F., Kaplan, D. R., and Cantley, L. C. (1997) Cell 88, 435-437[CrossRef][Medline] [Order article via Infotrieve]
17. Hemmings, B. A. (1997) Science 275, 628-630[Free Full Text]
18. Okada, T., Kawano, Y., Sabakibara, T., Hazeki, O., and Ui, M. (1994) J. Biol. Chem. 269, 3568-3573[Abstract/Free Full Text]
19. Kanai, F., Ito, K., Todaka, M., Hayashi, H., Kamohara, S., Ishii, K., Okada, T., Hazeki, O., Ui, M., and Ebina, Y. (1993) Biochem. Biophys. Res. Commun. 195, 762-768[CrossRef][Medline] [Order article via Infotrieve]
20. Kohn, A. D., Barthel, A., Kovacina, K. S., Boge, A., Wallach, B., Summers, S. A., Birnbaum, M. J., Scott, P. H., Lawrence, J. C., Jr., and Roth, R. A. (1998) J. Biol. Chem. 273, 11937-11943[Abstract/Free Full Text]
21. Kohn, A. D., Summers, S. A., Birnbaum, M. J., and Roth, R. A. (1996) J. Biol. Chem. 271, 31372-31378[Abstract/Free Full Text]
22. Kupriyanova, T. A., and Kandror, K. V. (1999) J. Biol. Chem. 274, 1458-1464[Abstract/Free Full Text]
23. Calera, M. R., Martinez, C., Liu, H., El Jack, A. K., Birnbaum, M. J., and Pilch, P. F. (1998) J. Biol. Chem. 273, 7201-7204[Abstract/Free Full Text]
24. Staubs, P. A., Nelson, J. G., Reichart, D. R., and Olefsky, J. M. (1998) J. Biol. Chem. 273, 25139-25147[Abstract/Free Full Text]
25. Brady, M. J., Bourbonais, F. J., and Saltiel, A. R. (1998) J. Biol. Chem. 273, 14063-14068[Abstract/Free Full Text]
26. Tanti, J. F., Grillo, S., Gremeaux, T., Coffer, P. J., Van Obberghen, E., and Le Marchand-Brustel, Y. (1997) Endocrinology 138, 2005-2010[Abstract/Free Full Text]
27. Summers, S. A., Lipfert, L., and Birnbaum, M. J. (1998) Biochem. Biophys. Res. Commun. 246, 76-81[CrossRef][Medline] [Order article via Infotrieve]
28. Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., Cahill, D. A., Goldstein, B. J., and White, M. F. (1991) Nature 352, 73-77[CrossRef][Medline] [Order article via Infotrieve]
29. Kamohara, S., Hayashi, H., Todaka, M., Kanai, F., Ishii, K., Imanaka, T., Escobedo, J. A., Williams, L. T., and Ebina, Y. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 1077-1081[Abstract/Free Full Text]
30. Quon, M. J., Chen, H., Lin, C. H., Zhou, L., Ing, B. L., Zarnowski, M. J., Klinghoffer, R., Kazlauskas, A., Cushman, S. W., and Taylor, S. I. (1996) Biochem. Biophys. Res. Commun. 226, 587-594[CrossRef][Medline] [Order article via Infotrieve]
31. Ricort, J.-M., Tanti, J.-F., Van Obberghen, E., and Le Marchand-Brustel, Y. (1997) J. Biol. Chem. 272, 19814-19818[Abstract/Free Full Text]
32. Sharma, P. M., Egawa, K., Huang, Y., Martin, J. L., Huvar, I., Boss, G. R., and Olefsky, J. M. (1998) J. Biol. Chem. 273, 18528-18537[Abstract/Free Full Text]
33. Altomare, D. A., Lyons, G. E., Mistsuuchi, Y., Cheng, J. Q., and Testa, J. R. (1998) Oncogene 16, 2407-2411[CrossRef][Medline] [Order article via Infotrieve]
34. Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S., and Kikuchi, A. (1998) EMBO J. 17, 1371-1384[CrossRef][Medline] [Order article via Infotrieve]
35. Cross, D. A., Watt, P. W., Shaw, M., van der Kaay, J., Downes, C. P., Holder, J. C., and Cohen, P. (1997) FEBS Lett. 406, 211-215[CrossRef][Medline] [Order article via Infotrieve]
36. Gingras, A., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., and Hay, N. (1998) Genes Dev. 12, 502-513[Abstract/Free Full Text]
37. Klippel, A., Reinhard, C., Kavanaugh, W. M., Apell, G., Escobedo, M. A., and Williams, L. T. (1996) Mol. Cell. Biol. 16, 4117-4127[Abstract]
38. Staal, S. P. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 5034-5037[Abstract/Free Full Text]
39. Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., and Testa, J. R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9267-9271[Abstract/Free Full Text]
40. van Weeren, P. C., de Bruyn, K. M. T., de Vries-Smits, A. M. M., van Lint, J., and Burgering, B. M. Th. (1998) J. Biol. Chem. 273, 13150-13156[Abstract/Free Full Text]
41. Kitamura, T., Ogawa, W., Sakaue, H., Hino, Y., Kuroda, S., Takata, M., Matsumoto, M., Maeda, T., Konishi, H., Kikkawa, U., and Kasuga, M. (1998) Mol. Cell. Biol. 18, 3708-3717[Abstract/Free Full Text]
42. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. (1997) Science 275, 661-665[Abstract/Free Full Text]
43. Meier, R., Alessi, D. R., Cron, P., Andjelkovic, M., and Hemmings, B. A. (1997) J. Chem. Biol. 272, 30491-30497[Abstract/Free Full Text]
44. Cong, L.-N., Chen, H., Li, Y., Zhou, L., McGibbon, M., Taylor, S., and Quon, M. (1997) Mol. Endocrinol. 11, 1881-1890[Abstract/Free Full Text]
45. Summers, S. A., Garza, L. A., Zhou, H., and Birnbaum, M. J. (1998) Mol. Cell. Biol. 18, 5457-5464[Abstract/Free Full Text]
46. Downward, J. (1998) Science 279, 673-674[Free Full Text]
47. Clark, S. F., Martin, S., Carozzi, A. J., Hill, M. M., and James, D. E. (1998) J. Cell Biol. 140, 1211-1225[Abstract/Free Full Text]
48. Jiang, T., Sweeney, G., Rudolf, M. T., Klip, A., Traynor-Kaplan, A., and Tsien, R. Y. (1998) J. Biol. Chem. 273, 11017-11024